Keyword Search
Legend:
CC = Vancouver Convention Centre F = Fairmont Waterfront Vancouver
* = applied session ! = JSM meeting theme
|
Keyword Search Criteria: Two-stage returned 34 record(s)
|
|
Sunday, 07/29/2018
|
Understanding Variance Estimator Bias in Stratified Two-Stage Sampling
Khoa Dong, U.S. Census Bureau; Timothy Trudell, US Census Bureau; Yang Cheng, US Census Bureau; Eric Slud, U.S. Census Bureau
2:25 PM
|
Dealing with Inaccurate Measures of Size in Two-Stage Probability Proportional to Size Sample Designs: Applications in African Household Surveys
Graham Kalton, Westat; Ismael Flores Cervantes, Westat; Carlos Arieira, Westat; Mike Kwanisai, Westat; Jehun Kim, Westat; Elizabeth Radin, ICAP at Columbia University; Suzue Saito, ICAP at Columbia University; Anindya De, U.S. Centers for Disease Control and Prevention; Stephen McCracken, U.S. Centers for Disease Control and Prevention; Paul Stupp, U.S. Centers for Disease Control and Prevention
3:20 PM
|
Q-Learning for Dynamic Treatment Regimes on CODIACS Vanguard Randomized Controlled Trial
Eun Jeong Oh, Columbia; Min Qian, Columbia University; Ying Kuen Ken Cheung, Columbia University
4:35 PM
|
Two-Stage Enrichment Clinical Trial Design with Adjustment for Misclassification in Predictive Biomarkers
Yong Lin, Rutgers, The State University of New Jersey; Weichung Joe Shih, Rutgers University; Shou-En Lu, Rutgers University
4:35 PM
|
|
Monday, 07/30/2018
|
Control of Two-Dimensional False Discovery Rate by Combining Two Univariate Multiple Testing Results with Application to Mass Spectral Data
Jaesik Jeong; Johan Lim, Seoul National University; Yongrae Kim, Seoul National University; Jong Soo Lee, University of Massachusetts
|
Uncertainty in the Design Stage of Two-Stage Bayesian Propensity Score Analysis
Shirley Liao
|
Efficient Two-Stage Designs and Proper Inference for Animal Studies
Chunyan Cai, UT Health Science Center at Houston; Jin Piao, University of Southern California; Jing Ning, The University of Texas M.D. Anderson Cancer Center; Xuelin Huang, University of Texas MD Anderson Cancer Center
9:05 AM
|
Design and Analysis Considerations for Studies Involving Pooled Biomarker Data
Abigail Sloan, Harvard T.H. Chan School of Public Health; Molin Wang, Harvard T.H. Chan School of Public Health; Mitchell H. Gail, Division of Cancer Epidemiology and Genetics, NCI, NIH
10:50 AM
|
Uncertainty in the Design Stage of Two-Stage Bayesian Propensity Score Analysis
Shirley Liao
10:50 AM
|
Statistical Issues in the Design and Analysis of Sequencing Studies
Danyu Lin, University of North Carolina
2:05 PM
|
|
Tuesday, 07/31/2018
|
A Two-Stage Microbial Association Mapping Framework with Advanced FDR Control
Jiyuan Hu, New York University School of Medicine; Huilin Li, New York University; Hyunwook Koh, NYU langone medical center; Linchen He, NYU langone medical center; Martin Blaser, New York University School of Medicine
|
A Two-Stage Method to Analyze Multivariate Cluster Biomarkers in Prediction on a Single Binary Outcome
Xiaoying Yu, University of Texas Medical Branch at Galveston; Wenyaw Chan, University of Texas Health Science Center at Houston; Gracie Vargas, University of Texas Medical Branch at Galveston; Rahul Pal, University of Texas Medical Branch at Galveston
|
A Two-Stage Microbial Association Mapping Framework with Advanced FDR Control
Jiyuan Hu, New York University School of Medicine; Huilin Li, New York University; Hyunwook Koh, NYU langone medical center; Linchen He, NYU langone medical center; Martin Blaser, New York University School of Medicine
9:30 AM
|
Multiplicity Adjustment for Multiple Endpoints Testing in Overall and Subgroup Populations
Libo Sun, Janssen Pharmaceutical R&D; Grace Liu, Johnson & Johnson; Rui Qin, Janssen Pharmaceutical R&D
9:35 AM
|
A Note on Phase II Single-Arm Two-Stage Designs for Safety
Seongho Kim, Wayne State University; Weng Kee Wong, UCLA
10:50 AM
|
A Two-Stage Method to Analyze Multivariate Cluster Biomarkers in Prediction on a Single Binary Outcome
Xiaoying Yu, University of Texas Medical Branch at Galveston; Wenyaw Chan, University of Texas Health Science Center at Houston; Gracie Vargas, University of Texas Medical Branch at Galveston; Rahul Pal, University of Texas Medical Branch at Galveston
11:10 AM
|
Copula Information Criterion for Two-Stage Maximum Likelihood
Vinnie Ko, University of Oslo; Nils Lid Hjort, University of Oslo
2:05 PM
|
|
Wednesday, 08/01/2018
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
|
Sample Size Formulae and Application for the Two-Stage Continual Reassessment Method (CRM)
Cody Chiuzan, Columbia University; Ying Kuen Ken Cheung, Columbia University; Zilan Chai, Columbia University
|
Multi-Frame Sampling Design for WTCHR
Sukhminder Osahan, NYC DOHMH
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
|
Multi-Frame Sampling Design for WTCHR
Sukhminder Osahan, NYC DOHMH
8:40 AM
|
Sample Size Formulae and Application for the Two-Stage Continual Reassessment Method (CRM)
Cody Chiuzan, Columbia University; Ying Kuen Ken Cheung, Columbia University; Zilan Chai, Columbia University
8:55 AM
|
Further Extensions of the Two-Stage Randomized Trial Design for Testing Treatment, Self-Selection and Treatment Preference Effects to Include Count Outcomes
Denise Esserman, Yale University; Yu Shi, Yale University
9:20 AM
|
A Curtailed Two-Stage Selection and Testing Procedure for Comparative Clinical Trials
Mingyue Wang, Syracuse University; Pinyuen Chen, Syracuse University
9:35 AM
|
A Two-Stage, Phase II Clinical Trial Design with Nested Criteria for Early Stopping and Efficacy: Expected Trial Duration and Tools for Planning
Michelle DeVeaux, Regeneron Pharmaceuticals; Michael John Kane, Yale University; Daniel Zelterman, Yale University
9:50 AM
|
On Randomized Controlled Trials with Integrated Real World Evidence for Drug Development in Rare Diseases
Qing Liu, Amicus Therapeutics, Inc
11:15 AM
|
|
Thursday, 08/02/2018
|
Causal Inference with Interference and Noncompliance in the Two-Stage Randomized Experiments
Zhichao Jiang, Princeton University; Kosuke Imai, Princeton University; Anup Malani, University of Chicago
10:35 AM
|
Evaluation of Treatment Effect: Beyond Traditional Subgroups
Yeh-Fong Chen, US FDA
10:55 AM
|
Bayesian Predictive Probability for Interim Analysis
Dung-Tsa Chen, Moffitt Cancer Center
11:05 AM
|
Developing Polygenic Risk Prediction Models for Cancer Subtypes Incorporating Multivariate Disease Characteristics
Haoyu Zhang, Johns Hopkins University; Thomas U. Ahearn, National Cancer Institute; Ni Zhao, Johns Hopkins University; Montserrat García-Closas, National Cancer Institute; Nilanjan Chatterjee, Johns Hopkins University
11:20 AM
|
A Modified Two-Stage Approach to the Interpretation of Forensic Evidence
Cami M. Fuglsby, South Dakota State University; Christopher P. Saunders, South Dakota State University; Danica Ommen, Iowa State University; JoAnn Buscaglia, FBI Laboratory, Counterterrorism & Forensic Science Research Unit
11:20 AM
|
Biomarker Guided Phase II Two-Stage Design for Targeted Therapy
Zheyu Wang, Johns Hopkins University; Fujun Wang, Medimmune; Chenguang Wang, Johns Hopkins University; Gary Rosner, Johns Hopkins University; Jianliang Zhang, Medimmune; Hao Wang, Johns Hopkins University; Li Shi, Medimmune
11:25 AM
|
Causal Effects in Partially and Non-Randomized Two-Stage Designs with Interference
Avi Feller, UC Berkeley; Samuel David Pimentel, University of California, Berkeley; Panos Toulis, University of Chicago; Guillaume Basse, Harvard University; Luke J. Keele, University of Pennsylvania
11:25 AM
|
|
|
